ALBO: Albireo Pharma, Inc. Yearly Stock Returns

Year	Beginning Price	Ending Price	Gain or Loss	Percent Gain or Loss
2008	23.23	4.82	-18.41	-79.25%
2009	4.82	4.34	-0.48	-9.96%
2010	4.34	1.83	-2.51	-57.83%
2011	1.83	0.61	-1.22	-66.67%
2012	0.61	0.5875*	-0.0225	-3.69%
2013	2.35	2.28	-0.07	-2.98%
2014	2.28	1.33	-0.95	-41.67%
2015	1.33	0.3426	-0.9874	-74.24%
2016	0.3426	0.591*	0.2484	72.50%
2017	17.73	25.60	7.87	44.39%
2018	25.60	24.53	-1.07	-4.18%
2019	24.53	25.42	0.89	3.63%
2020	25.42	37.51	12.09	47.56%
2021	37.51	23.29	-14.22	-37.91%
2022	23.29	21.61	-1.68	-7.21%
2023	21.61	52.00*	30.39	140.63%

*The 2012 ending price for Albireo Pharma has been adjusted for a 1 for 4 reverse stock split.
*The 2016 ending price for Albireo Pharma has been adjusted for a 1 for 30 reverse stock split.
*In 2023, Ipsen (IPSEY) acquired Albireo Pharma (ALBO) for $42 in cash and a $10 deferred cash payment upon approval of the drug Bylvay by the FDA.

Calculations do not reflect any dividends paid or any stock spinoffs from original stock. Taxes and commissions are not factored into calculations. Data is property of 1stock1 and written permission must be granted before redistributing any data (in part or in whole).